^
Association details:
| Biomarker: | MEN1 mutation + DAXX wild-type |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic correlates of response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine tumors.
Published date:
05/26/2022
Excerpt:
With and without accounting for line of therapy, we found that PFS on CAPTEM was significantly longer in MEN1-mutated, DAXX-wildtype tumors compared to other mutation profiles (P< 0.01)…We describe a novel genomic signature (MEN1 mut/DAXX wt) that correlates with PNET response to CAPTEM therapy and is exploratory in nature.
Secondary therapy:
capecitabine
DOI:
10.1200/JCO.2022.40.16_suppl.4124